Dividend Derby: AbbVie Vs. PfizerMotley FoolBiogen reported solid phase 2b data last spring for daclizumab, and AbbVie and Bristol-Myers reported solid mid stage results for elotuzumab in previously treated myeloma patients last summer. Fool-worthy fin…
|
BUSINESS | PRESS RELEASES
The Providence Journal Clinical data and the opinions of interviewed thought leaders indicate that Lemtrada, Biogen Idec/AbbVie’s daclizumab, and Roche/Genentech’s ocrelizumab offer improvements in ARR over first-line injectable mainstays (e.g., Teva’s Copaxone). Surveyed … |
|
Greater Effect on Disability Remains the Top Opportunity in Relapsing …
PR Newswire (press release) Clinical data and the opinions of interviewed thought leaders indicate that Lemtrada, Biogen Idec/AbbVie’s daclizumab, and Roche/Genentech’s ocrelizumab offer improvements in ARR over first-line injectable mainstays (e.g., Teva’s Copaxone). Surveyed … |
|
Biogen Idec Inc (BIIB) news: Biogen’s Winning Strategy
Seeking Alpha In the same segment Biogen and partner AbbVie (ABBV) are developing daclizumab high-yield process (HYP) in relapsing-remitting multiple sclerosis. The companies have completed a Phase 2b trial and expect the results of the Phase 3 study in mid-2014. |
The Utah People’s Post |
Biogen Faces Delay in FDA Action Date – Analyst Blog
NASDAQ In addition to Plegridy, Biogen has daclizumab in its MS pipeline. Biogen and partner AbbVie ( ABBV ) are conducting a two-year phase III study (DECIDE) on daclizumab with results due later this year. Biogen is also looking to expand Tysabri’s label … Biogen Idec Inc (NASDAQ:BIIB): A Biotech Pioneer With A Stellar FutureWallStreetPR |
Science World Report |
Biogen Faces Delay in FDA Action Date
Zacks.com Biogen is also looking to expand Tysabri’s label and is conducting a phase IIIb study (ASCEND) in combination with daclizumab in patients with secondary-progressive MS – results are expected in 2015. The delay in Plegridy’s approval date should not be … Biogen Idec Inc (NASDAQ:BIIB): A Biotech Pioneer With A Stellar FutureWallStreetPR |
Biogen Idec Inc (NASDAQ:BIIB): A Biotech Pioneer With A Stellar FutureWallStreetPRDaclizumab for RRMS is another drug in the pipeline. Tysabri is being developed for the treatment of SPMS. If this pans out, Tysabri sales might reach a peak of $5.2 bill…
iStockAnalyst (press release)Biogen Idec Inc (BIIB): Pipeline Offers Several Transformational OpportunitiesiStockAnalyst (press release)Upside potential beyond current estimates would include commercial success of Plegridy and daclizumab in Relapsing R…
|
Interleukin-Antagonisten: Hoch effektiv gegen Entzündungen
Pharmazeutische Zeitung online … eines Transplantats innerhalb der ersten zehn Tage nach der Operation sind vor allem die zytotoxischen T-Lymphozyten verantwortlich. In Kombination mit anderen Immunsuppressiva soll Basiliximab die Abstoßung einer transplantierten Niere verhindern. |
|
BMO Capital Upgrades Biogen (BIIB) to Outperform
StreetInsider.com (subscription) “With additional opportunities over the next 12 months for proof-of- concept with anti-LINGO for remyelination, TYSABRI in secondary progressive MS (SPMS), daclizumab in relapsing and remitting MS (RRMS), BIIB037 in Alzheimer’s, STX-100 in idiopathic … |